nach oben

Pediatric Nephrology

Erschienen in:

15.08.2018 | Educational Review

Should ACE inhibitors and ARBs be used in combination in children?

verfasst von: Brian R. Stotter, Michael A. Ferguson

Erschienen in: Pediatric Nephrology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in a host of renal and cardiovascular functions. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), drugs that disrupt RAAS function, are effective in treating hypertension and offer other renoprotective effects independent of blood pressure (BP) reduction. As our understanding of RAAS physiology and the feedback mechanisms of ACE inhibition and angiotensin receptor blockade have improved, questions have been raised as to whether combination ACEI/ARB therapy is warranted in certain patients with incomplete angiotensin blockade on one agent. In this review, we discuss the rationale for combination ACEI/ARB therapy and summarize the results of key adult studies and the limited pediatric literature that have investigated this therapeutic approach. We additionally review novel therapies that have been developed over the past decade as alternative approaches to combination ACEI/ARB therapy, or that may be potentially used in combination with ACEIs or ARBs, in which further adult and pediatric studies are needed.

Tigerstedt R, Bergman PG (1898) Niere und kreislauf. Skand Arch Physiol 8:223–271. https://doi.org/10.1111/j.1748-1716.1898.tb00272.x CrossRef

Goldbatt H, Lynch J, Hanzal RF, Summerville WW (1934) Studies on experimental hypertension: I. The production of persistent elevated systolic blood pressure by means of renal ischemia. J Exp Med 59(3):347–379. https://doi.org/10.1084/jem.59.3.347 CrossRef

Page IH (1937) Vasopressor action of extracts of plasma of normal dogs and dogs with experimentally produced hypertension. Proc Soc Exp Biol 35:112–116CrossRef

Leloir LF, Muñoz JM, Braun-Menéndez E, Fasciolo JC (1940) La secreción de la renina y la formación de hipertensina. Rev Soc Arg Biol 16:75–80

Skeggs LT Jr, Marsh WH, Kahn JR, Shumway NP (1954) The existence of two forms of hypertensin. J Exp Med 99(3):275–282CrossRef

Deane HW, Masson GM (1951) Adrenal cortical changes in rats with various types of experimental hypertension. J Clin Endocrinol Metab 11(2):193–208. https://doi.org/10.1210/jcem-11-2-193 CrossRefPubMed

Mulrow PJ, Ganong WF (1961) Stimulation of aldosterone secretion by angiotensin II. A preliminary report. Yale J Biol Med 33:386–395PubMedPubMedCentral

Ferreira SH (1965) A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Brit J Pharmacol 24:163–169PubMed

Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O (1971) Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis. Biochemistry 10(22):4033–4039CrossRef

10.

Ferguson RK, Turini GA, Brunner HR, Gavras H (1977) A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet 309(8015):775–778. https://doi.org/10.1016/S0140-6736(77)90297-5 CrossRef

11.

Brunner HR, Waeber B, Wauters JP, Turini G, McKinstry D, Gavras H (1978) Inappropriate renin secretion unmasked by captopril (SQ 14,225) in hypertension of chronic renal failure. Lancet 2(8092 Pt 1):704–707. https://doi.org/10.1016/S0140-6736(78)92703-4 CrossRefPubMed

12.

Case DB, Atlas SA, Laragh JH, Sealey JE, Sulivan PA, McKinstry DN (1978) Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis 21(3):195–206. https://doi.org/10.1016/0033-0620(78)90025-7 CrossRefPubMed

13.

Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA, McKinstry DN, Gavras I (1979) Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med 90(1):19–23. https://doi.org/10.7326/0003-4819-90-1-19 CrossRefPubMed

14.

Awan NA, Evenson MK, Needham KE, Win A, Mason DT (1981) Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. Am Heart J 101(1):22–31. https://doi.org/10.1016/0002-8703(81)90379-3 CrossRefPubMed

15.

Davis R, Ribner HS, Keung E, Sonnenblick EH, LeJemtel TH (1979) Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med 301(3):117–121. https://doi.org/10.1056/NEJM197907193010301 CrossRefPubMed

16.

Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O’Dea RF (1983) Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr 103(5):799–805. https://doi.org/10.1016/S0022-3476(83)80490-9 CrossRefPubMed

17.

Sinaiko AR, Kashtan CE, Mirkin BL (1986) Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Hypertens A 8(4–5):829–839PubMed

18.

O’Dea RF, Mirkin BL, Alward CT, Sinaiko AR (1988) Treatment of neonatal hypertension with captopril. J Pediatr 113(2):403–406. https://doi.org/10.1016/S0022-3476(88)80292-0 CrossRefPubMed

19.

Rhaleb NE, Rouissi N, Nantel F, D’Orleans-Juste P, Regoli D (1991) DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 17(4):480–484. https://doi.org/10.1161/01.HYP.17.4.480 CrossRefPubMed

20.

Ruggenenti P, Cravedi P, Remuzzi G (2010) The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 6:319–330. https://doi.org/10.1038/nrneph.2010.58 CrossRefPubMed

21.

Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE (1995) Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 10(11):1963–1974PubMed

22.

Coyle JD, Gardner SF, White CM (2004) The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. Ann Pharmacother 38(10):1731–1738. https://doi.org/10.1345/aph.1E182 CrossRefPubMed

23.

Taal MW, Brenner BM (2000) Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 57(5):1803–1817. https://doi.org/10.1046/j.1523-1755.2000.00031.x CrossRefPubMed

24.

Hoppu K (2008) Paediatric clinical pharmacology—at the beginning of a new era. Eur J Clin Pharmacol 64(2):201–205. https://doi.org/10.1007/s00228-007-0390-5 CrossRefPubMed

25.

European Medicines Agency (2014). Inventory of paediatric therapeutic needs: nephro-urology. Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500172596.pdf

26.

Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes mellitus: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321(7274):1440–1444. https://doi.org/10.1136/bmj.321.7274.1440 CrossRefPubMedPubMedCentral

27.

Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Mogensen CE (2005) Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 28(2):273–277. https://doi.org/10.2337/diacare.28.2.273 CrossRefPubMed

28.

Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET Investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372(9638):547–553. https://doi.org/10.1016/S0140-6736(08)61236-2 CrossRefPubMed

29.

Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Mann JF, ONTARGET and TRANSCEND Investigators (2011) Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 123(10):1098–1107. https://doi.org/10.1161/CIRCULATIONAHA.110.964171 CrossRefPubMed

30.

Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, VA NEPHRON-D Investigators (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369(20):1892–1903. https://doi.org/10.1056/NEJMoa1303154 CrossRefPubMed

31.

Duprez DA (2006) Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation; a clinical review. J Hypertens 24(6):983–991. https://doi.org/10.1097/01.hjh.0000226182.60321.69 CrossRefPubMed

32.

Lorenz JN, Weihprecht H, Schnermann J, Skøtt O, Briggs JP (1991) Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. Am J Phys 260(4 Pt 2):F486–F493. https://doi.org/10.1152/ajprenal.1991.260.4.F486 CrossRef

33.

Bock HA, Hermle M, Brunner FP, Thiel G (1992) Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int 41(2):275–280. https://doi.org/10.1038/ki.1992.39 CrossRefPubMed

34.

DiBona GF (1985) Neural regulation of renal tubular sodium reabsorption and renin secretion. Fed Proc 44(13):2816–2822PubMed

35.

Lu H, Cassis LA, Kooi CW, Daugherty A (2016) Structure and functions of angiotensinogen. Hypertens Res 39(7):492–500. https://doi.org/10.1038/hr.2016.17 CrossRefPubMedPubMedCentral

36.

Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 23(4):177–183. https://doi.org/10.1016/S0165-6147(00)01994-5 CrossRefPubMed

37.

Dinh DT, Frauman AG, Johnston CI, Fabiani ME (2001) Angiotensin receptors: distribution, signalling and function. Clin Sci 100(5):481–492. https://doi.org/10.1042/cs1000481 CrossRefPubMed

38.

Crowley SD, Gurley SB, Coffman TM (2007) AT(1) receptors and control of blood pressure: the kidney and more…. Trends Cardiovasc Med 17(1):30–34. https://doi.org/10.1016/j.tcm.2006.11.002 CrossRefPubMed

39.

Siragy HM (2004) AT1 and AT2 receptor in the kidney: role in health and disease. Semin Nephrol 24(2):93–100. https://doi.org/10.1016/j.semnephrol.2003.11.009 CrossRefPubMed

40.

Carey RM, Padia SH (2008) Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 19(3):84–87. https://doi.org/10.1016/j.tem.2008.01.003 CrossRefPubMed

41.

Schrier RW (2010) Aldosterone ‘escape’ vs. ‘breakthrough’. Nat Rev Nephrol 6(2):61. https://doi.org/10.1038/nrneph.2009.228 CrossRefPubMed

42.

Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR (1990) Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 15(2):276–282CrossRef

43.

Juillerat L, Nussberger J, Ménard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR (1990) Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16(5):564–572. https://doi.org/10.1161/01.HYP.16.5.564 CrossRefPubMed

44.

van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In’t Veld AJ, Schalekamp MA (1995) Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 25(1):22–29. https://doi.org/10.1161/01.HYP.25.1.22

45.

Ferrario CM, Ahmad S, Veragic J, Cheng CP, Groban L, Wang H, Collawn JF, Dell Italia LJ (2016) Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. Am J Physiol Heart Circ Physiol 311(2):H404–H414. https://doi.org/10.1152/ajpheart.00219.2016 CrossRefPubMedPubMedCentral

46.

Rykl J, Thiemann J, Kurzawski S, Pohl T, Gobom J, Zidek W, Schlüter H (2006) Renal cathepsin G and angiotensin II generation. J Hypertens 24(9):1797–1807. https://doi.org/10.1097/01.hjh.0000242404.91332.be CrossRefPubMed

47.

Hollenberg NK, Fisher ND, Price DA (1998) Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32(3):387–392. https://doi.org/10.1161/01.HYP.32.3.387 CrossRefPubMed

48.

Lu Y, Ku E, Campese VM (2010) Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Curr Hypertens Rep 12(4):303–306. https://doi.org/10.1007/s11906-010-0116-4 CrossRefPubMed

49.

Lijnen P, Staessen J, Fagard R, Amery A (1982) Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 49(6):1561–1563. https://doi.org/10.1016/0002-9149(82)90390-3 CrossRefPubMed

50.

Davis JO, Urquhart J, Higgins JT Jr (1963) The effects of alterations of plasma sodium and potassium concentration on aldosterone secretion. J Clin Invest 42(5):597–609. https://doi.org/10.1172/JCI104750 CrossRefPubMedPubMedCentral

51.

Hené RJ, Boer P, Koomans HA, Mees EJ (1982) Plasma aldosterone concentrations in chronic renal failure. Kidney Int 21(1):98–101. https://doi.org/10.1038/ki.1982.14 CrossRefPubMed

52.

Ménard J, Campbell DJ, Azizi M, Gonzales MF (1997) Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96(9):3072–3080. https://doi.org/10.1161/01.CIR.96.9.3072 CrossRefPubMed

53.

Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME (2001) Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci 100(6):591–599. https://doi.org/10.1042/cs1000591 CrossRefPubMed

54.

Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z (2003) Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin Sci 104(4):341–347. https://doi.org/10.1042/cs1040341 CrossRefPubMed

55.

Yagi S, Morita T, Katayama S (2004) Combined treatment of an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 27(2):129–135. https://doi.org/10.1291/hypres.27.129 CrossRefPubMed

56.

Schmerbach K, Kalk P, Wengenmayer C, Lucht K, Unger T, Hocher B, Thoene-Reineke C (2012) Renal outcome in equipotent antihypertensive treatment with telmisartan, ramipril and in combination in SHR-SP rats. Clin Lab 58(7–8):625–633. https://doi.org/10.7754/Clin.Lab.2011.110622 CrossRefPubMed

57.

Lo CS, Liu F, Shi Y, Maachi H, Chenier I, Godin N, Filep JG, Ingelfinger JR, Zhang SL, Chan JS (2012) Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol 302(7):F840–F852. https://doi.org/10.1152/ajprenal.00340.2011 CrossRefPubMed

58.

Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J (1995) Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92(4):825–834. https://doi.org/10.1161/01.CIR.92.4.825 CrossRefPubMed

59.

Azizi M, Guyene TT, Chatellier G, Wargon M, Ménard J (1997) Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 29(2):634–640. https://doi.org/10.1161/01.HYP.29.2.634 CrossRefPubMed

60.

Azizi M, Linhart A, Alexander J, Goldberg A, Menten J, Sweet C, Ménard J (2000) Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 18(8):1139–1147CrossRef

61.

Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang RY (2001) Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 14(6 Pt 1):567–572. https://doi.org/10.1016/S0895-7061(00)01304-2 CrossRefPubMed

62.

Sarnak MJ, Astor BC (2011) Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis 18(4):258–266. https://doi.org/10.1053/j.ackd.2011.04.002 CrossRefPubMed

63.

Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen A, Sallay P, Jeck N, Berg U, Çaliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F, ESCAPE Trial Group (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361(17):1639–1650. https://doi.org/10.1056/NEJMoa0902066

64.

van den Belt SM, Heerspink HJL, Gracchi V, de Zeeuw D, Wühl E, Schaefer F; ESCAPE Trial Group (2018) Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol Advanced online publication https://doi.org/10.1681/ASN.2018010036

65.

De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110(8):921–927. https://doi.org/10.1161/01.CIR.0000139860.33974.28 CrossRefPubMed

66.

Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R (1999) Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33(5):851–856. https://doi.org/10.1016/S0272-6386(99)70416-6 CrossRefPubMed

67.

Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P (2002) Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int Supp 82:S47–S52. https://doi.org/10.1046/j.1523-1755.62.s82.10.x CrossRef

68.

Kanno Y, Takenaka T, Nakamura T, Suzuki H (2006) Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 1(4):730–737. https://doi.org/10.2215/CJN.01110905 CrossRefPubMed

69.

Litwin M, Grenda R, Sladowska J, Antoniewicz J (2006) Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol 21:1716–1722. https://doi.org/10.1007/s00467-006-0223-2 CrossRefPubMed

70.

Seeman T, Pohl M, Misselwitz J, John U (2009) Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with angiotensin-converting enzyme inhibitors. Kidney Blood Press Res 32(6):440–444. https://doi.org/10.1159/000266478 CrossRefPubMed

71.

Caletti MG, Balestracci A, Missoni M, Vezzani C (2013) Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. Pediatr Nephrol 28(5):745–750. https://doi.org/10.1007/s00467-012-2374-7 CrossRefPubMed

72.

Zhang Y, Wang F, Ding J, Zhang H, Liu X, Wang S, Xiao H, Yao Y, Liu J, Zhong X, Guan N, Su B, Wu G, Yu L (2016) Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome. Pediatr Nephrol 31(1):67–72. https://doi.org/10.1007/s00467-015-3184-5 CrossRefPubMed

73.

Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G (2017) Achieving remission of proteinuria in childhood CKD. Pediatr Nephrol 32(2):321–330. https://doi.org/10.1007/s00467-016-3495-1 CrossRefPubMed

74.

Chandar J, Abitbol C, Montané B, Zilleruelo G (2007) Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrol Dial Transplant 22(5):1332–1337. https://doi.org/10.1093/ndt/gfl839 CrossRefPubMed

75.

Lubrano R, Soscia F, Elli M, Ventriglia F, Raggi C, Travasso E, Scateni S, Di Maio V, Versacci P, Masciangelo R, Romero S (2006) Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria. Pediatrics 118(3):e833–e838. https://doi.org/10.1542/peds.2005-2053 CrossRefPubMed

76.

Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger ZM (2015) Angiotensin-converting enzyme inhibitor-induced angioedema. Am J Med 128(2):120–125. https://doi.org/10.1016/j.amjmed.2014.07.011 CrossRefPubMed

77.

Baker-Smith CM, Benjamin DK Jr, Califf RM, Murphy MD, Li JS, Smith PB (2010) Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 87(6):668–671. https://doi.org/10.1038/clpt.2009.231 CrossRefPubMedPubMedCentral

78.

Assadi FK, Wang HE, Lawless S, McKay CP, Hopp L, Fattori D (1999) Angiotensin converting enzyme inhibitor-induced angioedema: a report of two cases. Pediatr Nephrol 13(9):917–919. https://doi.org/10.1007/s004670050727 CrossRefPubMed

79.

Quintana EC, Attia MW (2001) Angiotensin-converting enzyme inhibitor angioedema in a pediatric patient: a case report and discussion. Pediatr Emerg Care 17(6):438–440CrossRef

80.

Hom KA, Hirsch R, Elluru RG (2012) Antihypertensive drug-induced angioedema causing upper airway obstruction in children. Int J Pediatr Otorhinolaryngol 76(1):14–19. https://doi.org/10.1016/j.ijporl.2011.07.016 CrossRefPubMed

81.

Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF (2014) The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol 21(3):299–309. https://doi.org/10.1177/2047487313510678 CrossRefPubMed

82.

Chan KE, Ikazler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ (2011) Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int 80(9):978–985. https://doi.org/10.1038/ki.2011.228 CrossRefPubMedPubMedCentral

83.

Kido R, Akizawa T, Fukagawa M, Onishi Y, Yamaguchi T, Fukuhara S (2017) Interactive effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers or their combination on survival of hemodialysis patients. Am J Nephrol 46(6):439–447. https://doi.org/10.1159/000482013 CrossRefPubMedPubMedCentral

84.

Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A (2007) Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 1(4):264–277. https://doi.org/10.1016/j.jash.2007.04.004 CrossRefPubMed

85.

Verdecchia P, Angeli F, Mazzotta G, Martire P, Garofoli M, Gentile G, Reboldi G (2010) Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis 4(3):193–200. https://doi.org/10.1177/1753944710369682 CrossRefPubMed

86.

Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A (2007) Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 20(1):11–20. https://doi.org/10.1016/j.amjhyper.2006.06.003 CrossRefPubMed

87.

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B, Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators (2009) Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119(4):530–537. https://doi.org/10.1161/CIRCULATIONAHA.108.826214 CrossRefPubMed

88.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358(23):2433–2446. https://doi.org/10.1056/NEJMoa0708379 CrossRefPubMed

89.

Uzu T, Araki SI, Kashiwagi A, Haneda M, Koya D, Yokoyama H, Kida Y, Ikebuchi M, Nakamura T, Nishimura M, Takahara N, Obata T, Omichi N, Sakamoto K, Shingu R, Taki H, Nagai Y, Tokuda H, Kitada M, Misawa M, Nishiyama A, Kobori H, Maegawa H, Shiga Committee for Preventing Diabetic Nephropathy (2016) Comparative effects of direct renin inhibitor and angiotensin receptor blocker on albuminuria in hypertensive patients with type 2 diabetes—a randomized controlled trial. PLoS One 11(12):e0165936. https://doi.org/10.1371/journal.pone.0164936 CrossRef

90.

Soji K, Doi S, Nakashima A, Sasaki K, Kawai T, Aoki A, Kyuden Y, Fujiwara K, Yokoyama Y, Masaki T (2015) Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study. Clin Exp Nephrol 19(4):631–638. https://doi.org/10.1007/s10157-014-1044-4 CrossRefPubMed

91.

Li SY, Chen YT, Yang WC, Tarng DC, Lin CC, Yang CY, Liu WS (2012) Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease. BMC Nephrol 13:89. https://doi.org/10.1186/1471-2369-13-89 CrossRefPubMedPubMedCentral

92.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367(23):2204–2213. https://doi.org/10.1056/NEJMoa1208799 CrossRefPubMed

93.

Sullivan JE, Keefe D, Zhou Y, Satlin L, Fang H, Yan JH (2013) Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clin Pediatr 52(7):599–607. https://doi.org/10.1177/0009922813483875 CrossRef

94.

Kelland EE, McAuley LM, Filler G (2011) Are we ready to use aliskiren in children? Pediatr Nephrol 26(3):473–477. https://doi.org/10.1007/s00467-010-1702-z CrossRefPubMed

95.

Flynn JT (2011) Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children. Pediatr Nephrol 26(3):491–492. https://doi.org/10.1007/s00467-010-1726-4 CrossRefPubMed

96.

Shibata S, Ishizawa K, Uchida S (2017) Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. Hypertens Res 40(3):221–225. https://doi.org/10.1038/hr.2016.137 CrossRefPubMed

97.

Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD (2009) Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20(12):2641–2650. https://doi.org/10.1681/ASN.2009070737 CrossRefPubMedPubMedCentral

98.

Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T, EVALUATE Study Group (2014) Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2(12):944–953. https://doi.org/10.1016/S2213-8587(14)70194-9 CrossRefPubMed

99.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM, Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884–894. https://doi.org/10.1001/jama.2015.10081 CrossRefPubMed

100.

Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M (2013) Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrol Dial Transplant 28(11):2823–2833. https://doi.org/10.1093/ndt/gft281 CrossRefPubMed

101.

Judge P, Haynes R, Landray MJ, Baigent C (2015) Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant 30(5):738–743. https://doi.org/10.1093/ndt/gfu269 CrossRefPubMed

Titel: Should ACE inhibitors and ARBs be used in combination in children?
verfasst von: Brian R. Stotter
Michael A. Ferguson
Publikationsdatum: 15.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 9/2019
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-018-4046-8

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Should ACE inhibitors and ARBs be used in combination in children?

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Relationship between food insecurity and high blood pressure in a national sample of children and adolescents

Bialleleic PKD1 mutations underlie early-onset autosomal dominant polycystic kidney disease in Saudi Arabian families

A child with bilateral multiple renal cysts presenting with ascites and pleural effusion: Answers

Comments on Tașdemir et al.: A rare cause of AA amyloidosis and end-stage kidney failure

A child with bilateral multiple renal cysts presenting with ascites and pleural effusion: Questions

Estimating glomerular filtration rate in youth with obesity and type 2 diabetes: the iCARE study equation

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie